ANPAC BIO-MEDICAL SCIENC-ADR (ANPC) Stock Price, Forecast & Analysis
USA - NASDAQ:ANPC - US03635R2067 - ADR
ANPC Key Statistics, Chart & Performance
The current stock price of ANPC is 4.37 USD. In the past month the price decreased by -23.5%. In the past year, price decreased by -27.14%.
ANPC Latest News, Press Relases and Analysis
ANPC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 382.94B | ||
| AMGN | AMGEN INC | 14.63 | 172.20B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 106.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.31 | 68.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.08 | 56.96B | ||
| ARGX | ARGENX SE - ADR | 62.07 | 51.25B | ||
| INSM | INSMED INC | N/A | 39.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.19 | 35.30B | ||
| NTRA | NATERA INC | N/A | 27.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.86B | ||
| BIIB | BIOGEN INC | 9.17 | 22.49B |
Related stock screener links
About ANPC
Company Profile
Anpac Bio-Medical Science Co., Ltd., is a biotechnology company. The company is headquartered in Lishui, Zhejiang and currently employs 89 full-time employees. The company went IPO on 2020-01-30. The firm markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The firm have established two clinical laboratories in China and one clinical laboratory in the United States. The firm is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, internet, and Web3 transformation of start-ups and traditional enterprises.
Company Info
ANPAC BIO-MEDICAL SCIENC-ADR
801 Bixing Street, Bihu County
Lishui ZHEJIANG 323006 CN
CEO: Chris Chang Yu
Employees: 89
Phone: 8657820516666.0
ANPAC BIO-MEDICAL SCIENC-ADR / ANPC FAQ
What does ANPC do?
Anpac Bio-Medical Science Co., Ltd., is a biotechnology company. The company is headquartered in Lishui, Zhejiang and currently employs 89 full-time employees. The company went IPO on 2020-01-30. The firm markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The firm have established two clinical laboratories in China and one clinical laboratory in the United States. The firm is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, internet, and Web3 transformation of start-ups and traditional enterprises.
Can you provide the latest stock price for ANPAC BIO-MEDICAL SCIENC-ADR?
The current stock price of ANPC is 4.37 USD. The price decreased by -5.41% in the last trading session.
Does ANPAC BIO-MEDICAL SCIENC-ADR pay dividends?
ANPC does not pay a dividend.
How is the ChartMill rating for ANPAC BIO-MEDICAL SCIENC-ADR?
ANPC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How many employees does ANPAC BIO-MEDICAL SCIENC-ADR have?
ANPAC BIO-MEDICAL SCIENC-ADR (ANPC) currently has 89 employees.
What is the market capitalization of ANPC stock?
ANPAC BIO-MEDICAL SCIENC-ADR (ANPC) has a market capitalization of 180.61M USD. This makes ANPC a Micro Cap stock.
Can you provide the upcoming earnings date for ANPAC BIO-MEDICAL SCIENC-ADR?
ANPAC BIO-MEDICAL SCIENC-ADR (ANPC) will report earnings on 2023-06-29.
ANPC Technical Analysis
ANPC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ANPC. Both the profitability and financial health of ANPC have multiple concerns.
ANPC Financial Highlights
Over the last trailing twelve months ANPC reported a non-GAAP Earnings per Share(EPS) of -13.38. The EPS increased by 29.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ANPC Forecast & Estimates
7 analysts have analysed ANPC and the average price target is 8.16 USD. This implies a price increase of 86.73% is expected in the next year compared to the current price of 4.37.